J3111 HCPCS code: Injection, romosozumab-aqqg, 1 mg
J3111 is the HCPCS Level II code for injection, romosozumab-aqqg, 1 mg. In 2024 Medicare paid an average of $8.49 per service for J3111 across 39,897,020 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 210 per day on outpatient hospital claims. Medicare volume rose 76% from 2022 to 2024 (22,656,594 to 39,897,020 services). In 2024, about 6,820 clinicians billed Medicare for J3111 for 35,551 beneficiaries; Florida, California, Texas accounted for 33% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2019-10-01 |
| Last action effective | 2019-10-01 |
Who bills J3111 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 6,820 |
| Medicare beneficiaries | 35,551 |
| States with claims | 51 |
| Share of services in top 3 states (Florida, California, Texas) | 33% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J3111, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 22,656,594 | 20,272 | $9.38 | $7.46 |
| 2023 | 31,497,390 | 28,185 | $9.92 | $7.87 |
| 2024 | 39,897,020 | 35,551 | $10.69 | $8.49 |
States with the most J3111 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Florida | 4,949,710 | $8.49 |
| California | 4,663,238 | $8.48 |
| Texas | 3,498,976 | $8.50 |
| Pennsylvania | 2,395,899 | $8.52 |
| Illinois | 1,891,494 | $8.53 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 210 | Prescribing Information |
| practitioner claims | 210 | Prescribing Information |
What changed for J3111
- 2019-10-01: J3111 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J3111?
J3111 is the HCPCS Level II code for injection, romosozumab-aqqg, 1 mg. Short descriptor: "Inj. romosozumab-aqqg 1 mg".
How much does Medicare pay for J3111?
In 2024, the average Medicare payment was $8.49 per service (average allowed $10.69).
Does Medicare cover J3111?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J3111 can be billed per day?
210 on outpatient hospital claims; 210 on practitioner claims (NCCI medically unlikely edits).
Related J31 codes
- J3101 — Injection, tenecteplase, 1 mg
- J3105 — Injection, terbutaline sulfate, up to 1 mg
- J3110 — Injection, teriparatide, 10 mcg
- J3120 — Injection, testosterone enanthate, up to 100 mg
- J3121 — Injection, testosterone enanthate, 1 mg
- J3130 — Injection, testosterone enanthate, up to 200 mg
- J3140 — Injection, testosterone suspension, up to 50 mg
- J3145 — Injection, testosterone undecanoate, 1 mg
- J3150 — Injection, testosterone propionate, up to 100 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J3111
- Watch J3111 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J3111
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.